{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-23-000011","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.116716+00:00","generated_at":"2026-06-14T16:04:46.504016+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbCellera enters $701M co-investment with Canadian, BC governments for antibody drug development","bullets":["CA$701M co-investment: AbCellera invests CA$401M, Canada CA$225M, BC CA$75M over 8 years.","Builds capabilities to develop antibody drugs from target identification through Phase 1 clinical trials.","Initial focus on cancer and immune diseases; plans to initiate up to 17 new drug development programs.","Expected to create hundreds of new high-skilled jobs in Canada across computer science, life sciences, and manufacturing.","Government contributions include repayable and conditionally repayable portions starting in 2032-2033."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-23-000011","json":"https://secwatch.observer/filing/0001703057-23-000011.json","markdown":"https://secwatch.observer/filing/0001703057-23-000011.md","text":"https://secwatch.observer/filing/0001703057-23-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/0001703057-23-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/abcl-20230524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T16:04:46.504016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba6c2cd2ec9cf46e88f8fd6629ea1f5e49952489","claim":"AbCellera Biologics Inc. entered into Canada Contribution Agreement with Government of Canada valued at Up to $166.7 million (CA$225.0 million) including non-repayable, repayable, and conditionally repaya (effective 2023-05-24).","evidence_excerpt":"Pursuant to the Canada Contribution Agreement, the Government of Canada has committed up to $166.7 million (CA$225.0 million), of which $41.6 million (CA$56.2 million) is not repayable, $58.4 million (CA$78.8 million) is repayable and $66.7 million (CA$90.0 million) is conditionally repayable.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/0001703057-23-000011-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Government of Canada"},{"label":"Value","value":"Up to $166.7 million (CA$225.0 million) including non-repayable, repayable, and conditionally repaya"},{"label":"Effective","value":"2023-05-24"}],"fact_type":"material_agreement"},{"claim_id":"f34ef0a4fffcfea49d24c642e43e89c3f3a06e91","claim":"AbCellera Biologics Inc. entered into BC Contribution Agreement with Government of British Columbia valued at Up to $55.6 million (CA$75.0 million) including partial reimbursement and conditional portions. (effective 2023-05-24).","evidence_excerpt":"Pursuant to the BC Contribution Agreement, the Government of British Columbia has committed up to $55.6 million (CA$75.0 million) which includes partial reimbursement of certain eligible expenditures up to $27.8 million (CA$37.5 million) towards eligible infrastructure investments paid over five years; and a $27.8 million (CA$37.5 million) conditional portion paid upon achievement of certain defined milestones, including upon the Company’s undertaking of certain clinical trial activities in British Columbia.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/0001703057-23-000011-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Government of British Columbia"},{"label":"Value","value":"Up to $55.6 million (CA$75.0 million) including partial reimbursement and conditional portions."},{"label":"Effective","value":"2023-05-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}